• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement

by MM360 Staff | Jul 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Expert: Linvoseltamab’s Simplified Dosing Expands Access, Enhances Tolerability in Multiple Myeloma

by MM360 Staff | Jul 31, 2025 | Myeloma News

Source: Pharmacy Times articles Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients. Read More

LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy

by MM360 Staff | Jul 28, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease

by MM360 Staff | Jul 28, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

EHA 2025: Early Data Support Tocilizumab Use to Enable Outpatient Talquetamab Dosing in R/R Multiple Myeloma

by MM360 Staff | Jul 24, 2025 | Myeloma News

Source: Pharmacy Times articles Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma. Read More

NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma

by MM360 Staff | Jul 19, 2025 | Myeloma News

Source: Pharmacy Times articles The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing...
« Older Entries
Next Entries »

Recent Content

  • Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus
  • Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma
  • Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
  • Video: Pharmacists Take Center Stage in Delivering Linvoseltamab, Advancing Myeloma Care
  • SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma
  • FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma
  • Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT
  • Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
  • Expert: Linvoseltamab’s Simplified Dosing Expands Access, Enhances Tolerability in Multiple Myeloma
  • Patient Perspective: Navigating Multiple Myeloma Treatment
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT